Science & Enterprise subscription

Follow us on Twitter

  • A company developing health metrics with artificial intelligence received a grant to better understand polycystic o… https://t.co/ElPrTv6NfS
    about 11 hours ago
  • New post on Science and Enterprise: Small Biz Grant Funds AI Repro Health Technology https://t.co/kf8kmvP8Xa #Science #Business
    about 11 hours ago
  • The Food and Drug Administration began a pilot program for assessing alternative technologies to test drugs, biolog… https://t.co/r5mRCGGL4B
    about 16 hours ago
  • New post on Science and Enterprise: FDA Begins Qualifying Non-Animal Testing Options https://t.co/pf0GN32FfV #Science #Business
    about 16 hours ago
  • A new enterprise is developing personalized digital therapeutics for people with Alzheimer's disease and other neur… https://t.co/aFxlnK5VHH
    about 1 day ago

Please share Science & Enterprise

Biotech Gets DARPA Grant for Respiratory Therapies

Anthrax spores (U.S. Food and Drug Administration)

Anthrax spores (U.S. Food and Drug Administration)

Pulmatrix, a biotechnology company in Lexington, Massachusetts, said today it received a grant for $5.7 million from the Defense Advanced Research Projects Agency (DARPA) in the Department of Defense, to further develop the company’s processes for the treatment and prevention of respiratory infections.

DARPA identified Pulmatrix’s inhaled cationic airway lining modulators (iCALM) technology as a candidate for the development of therapeutics for the treatment and prevention of respiratory infections caused by weaponized, engineered, or naturally occurring pathogens. iCALM therapies trigger multiple mechanisms that act together on the physical properties and host defenses of the airway, and can work against against an array of pathogens with reduced potential for resistance.

The award will support formulation development and preclinical studies to evaluate the range and efficacy of potential iCALM drug candidates. The most promising formulations will be selected for investigational new drug toxicology studies leading into clinical development with the goal of providing a field-deployable drug/device combination to protect service members and civilians against an array of airborne threats including anthrax, tularemia, and different strains of influenza.

Related: Three Companies Win NIH Biodefense Research Contracts

*     *     *

Comments are closed.